Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR.
Javier EscanedDavide CaoUsman BaberJohny NicolasSamantha SartoriZhongjie ZhangGeorge DangasDominick J AngiolilloCarlo BriguoriDavid Joel CohenStuart J PocockDariusz DudekMichael GibsonRobert J GilKurt HuberUpendra KaulRan KornowskiMitchell W KrucoffVijay KunadianShamir MehtaDavid J MoliternoE Magnus OhmanKeith G OldroydGennaro SardellaSamin K SharmaRichard A ShlofmitzGiora WeiszBernhard WitzenbichlerStuart PocockRoxana MehranPublished in: European heart journal (2021)
Among HBR patients undergoing PCI who completed 3-month DAPT without experiencing major adverse events, aspirin discontinuation followed by ticagrelor monotherapy significantly reduced bleeding without increasing ischaemic events, compared with ticagrelor plus aspirin. The absolute risk reduction in major bleeding was larger in HBR than non-HBR patients.
Keyphrases
- antiplatelet therapy
- percutaneous coronary intervention
- acute coronary syndrome
- st segment elevation myocardial infarction
- atrial fibrillation
- st elevation myocardial infarction
- acute myocardial infarction
- coronary artery disease
- coronary artery bypass grafting
- patients undergoing
- end stage renal disease
- ejection fraction
- low dose
- prognostic factors
- chronic kidney disease
- newly diagnosed
- combination therapy
- coronary artery bypass
- open label
- type diabetes
- peritoneal dialysis
- patient reported outcomes
- randomized controlled trial